One of the most consistent findings in GLP-1 body composition research is that not all the weight people lose on these drugs is fat. A meaningful share is lean mass, which includes muscle, and researchers are actively studying both how much that matters clinically and how to reduce it.

How Much of the Weight Lost Is Lean Mass

Body composition substudies of major GLP-1 trials, including the DXA-scan substudy within the SURMOUNT-1 tirzepatide trial, have found that roughly a quarter of total weight lost during treatment is lean mass, with the remainder coming from fat. That ratio is broadly in the range seen with weight loss from calorie restriction generally, meaning it isn't unique to these drugs, but the amount of weight lost is often larger and faster with GLP-1 therapy than with diet alone, so the absolute amount of lean mass lost can be larger too. A more recent digital phenotyping analysis, posted in 2026 as a preprint and not yet peer-reviewed, reported greater lean-body-mass decline with tirzepatide than with semaglutide in routine clinical care, though preprint findings should be treated as preliminary until they go through peer review.

Why This Might Matter Clinically

Muscle plays a role in metabolic health, physical strength, fall risk, and resting metabolic rate. For older adults in particular, unintentional loss of muscle mass, sometimes called sarcopenia when severe, is associated with frailty and reduced quality of life. A separate strand of research, though, including a study published in Cell Reports Medicine, has reported that weight loss with GLP-1 medicines does not appear to cause a disproportionate loss of muscle mass or function relative to the amount of fat lost, in both animal models and human data reviewed. Put together, the research picture is genuinely mixed: lean mass loss is real and measurable, but whether it translates into meaningfully worse strength or function outcomes than any other form of significant weight loss is still being actively debated rather than settled.

What's Being Done to Address It

Several strategies are being studied or recommended alongside GLP-1 therapy specifically to help preserve lean mass, including structured resistance exercise training and adequate dietary protein intake during treatment. Neither is a guarantee, but both have physiological rationale: resistance training provides the mechanical stimulus that helps maintain muscle even during a calorie deficit, and adequate protein intake supplies the building blocks muscle needs to avoid excessive breakdown. Separately, and more directly related to drug development, the amylin agonist pathway, covered in more detail in this site's guide to amylin agonists, is being explored partly because early data suggests combining an amylin agonist with a GLP-1 drug may preserve a more favorable ratio of fat loss to lean mass loss than a GLP-1 drug alone, though this remains an active area of research rather than an established advantage.

What This Isn't

None of this research suggests that GLP-1 drugs cause dangerous or unique muscle-wasting disease. The concern researchers are studying is a matter of degree and ratio, how much of a person's weight loss is fat versus muscle, and whether that ratio can be improved, not a claim that these drugs are unsafe for the muscles specifically. It's also worth separating this from unrelated marketing claims sometimes made about "research chemical" peptides claiming to build or preserve muscle; those products, discussed elsewhere on this site, carry their own separate, generally much weaker evidence base and are not FDA-approved treatments for this purpose.

The Bottom Line

Lean mass loss during GLP-1 treatment is real, well-documented, and worth taking seriously, particularly for older adults or anyone starting from a lower muscle mass baseline. At the same time, the current evidence doesn't support the idea that this represents a disproportionate or dangerous loss of muscle function compared with other forms of substantial weight loss. Resistance training, adequate protein intake, and newer combination approaches under study are the main strategies being explored to improve that ratio.

Talk to Your Doctor

If you're on or considering a GLP-1 medication and are concerned about muscle loss, ask your doctor about incorporating resistance training and protein intake targets into your plan, and whether monitoring your body composition over time makes sense for your situation. This article is educational and isn't a substitute for that conversation.